Physician profile
Nathan Pyle
NPI 1174821540
$4,789.97
in general payments reported to CMS, 2019-2025
26 companies · $596 in 2025
The $596 reported for 2025 was less than what a typical Gastroenterology (Internal Medicine) provider received nationally (typical 2025 total: $636).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,648 · 2020: $356 · 2021: $949 · 2022: $601 · 2023: $486 · 2024: $153 · 2025: $596.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $963 · Education: $272.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $963.17 |
| Education | $271.95 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,843.26 | 2019-2025 | |
| Takeda Pharmaceuticals U.S.A., INC. | $629.01 | 2019-2025 | Entyvio |
| Janssen Biotech, INC. | $399.39 | 2019-2025 | Tremfya, Stelara |
| Nestle Healthcare Nutrition INC. | $295.57 | 2021-2023 | |
| Pfizer INC. | $212.72 | 2019-2024 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $184.34 | 2019-2021 | |
| Madrigal Pharmaceuticals | $161.46 | 2025 | Rezdiffra |
| Gilead Sciences, INC. | $143.50 | 2019-2023 | |
| Ucb, INC. | $143.20 | 2019 | |
| Merck Sharp & Dohme LLC | $127.81 | 2019-2023 | Dificid |
| Janssen Pharmaceuticals, INC | $118.90 | 2019-2025 | |
| Braintree Laboratories, INC. | $110.35 | 2019-2023 | Sutab |
| Intercept Pharmaceuticals, INC. | $87.96 | 2019-2022 | |
| Ardelyx, INC. | $66.77 | 2024-2025 | Ibsrela |
| Aimmune Therapeutics, INC. | $42.88 | 2025 | Zenpep |
Show all 26 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Clovis Oncology, INC. | $35.58 | 2019 | |
| Amgen INC. | $31.79 | 2021 | |
| Shionogi INC | $30.44 | 2019 | |
| Alfasigma USA, INC. | $22.40 | 2020 | |
| W. L. Gore & Associates, INC. | $18.99 | 2021 | |
| Pharmacyclics LLC, An Abbvie Company | $15.21 | 2020 | |
| Eisai INC. | $14.62 | 2020 | |
| Astrazeneca Pharmaceuticals Lp | $14.25 | 2019 | |
| Dova Pharmaceuticals | $14.07 | 2019 | |
| Puma Biotechnology, INC. | $12.96 | 2020 | |
| Ambu INC. | $12.54 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Nathan Pyle listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.